# iECURE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iecure

- Industry: Biotechnology
- Headquarters: Plymouth Meeting, US
- Website: www.iecure.com
- Total disclosed funding: $115M
- Latest round: Series A (Nov 30, 2022)
- Investors on record: 4

## About

iECURE, Inc. is a US-based biotechnology company focused on innovative gene therapy solutions for rare liver diseases, particularly those caused by genetic mutations, aiming to improve patient outcomes through advanced therapeutic techniques.iECURE, Inc. specializes in developing gene therapy products targeting rare, monogenic liver diseases. Founded in 2020 and headquartered in Plymouth Meeting, Pennsylvania, the company has successfully completed 2 deals, with the most recent being a SERIES A funding round in November 2022, raising USD 65 mn. The CEO, Joseph Truitt, leads the company as it continues to advance its clinical pipeline. iECURE collaborates with the University of Pennsylvania’s Gene Therapy Program for research initiatives.iECURE specializes in advanced gene therapy solutions focused on treating rare, monogenic liver diseases, particularly those characterized by 'loss of function' disorders. Their core offering is the ECUR-506, a mutation-agnostic in vivo gene insertion therapy designed to deliver healthy copies of disease-causing genes directly into patients’ chromosomes. This innovative approach aims to reverse the effects of genetic disorders such as ornithine transcarbamylase (OTC) deficiency, significantly improving patient outcomes by providing long-term, stable expression of necessary genes. The company collaborates closely with the University of Pennsylvania’s Gene Therapy Program, leveraging their expertise to enhance its research and development initiatives, targeting patients with rare genetic conditions, healthcare providers, and research institutions across North America and Europe.Revenue generation for iECURE is primarily structured around clinical trial partnerships and collaborations with key academic institutions and healthcare organizations. These partnerships facilitate the development and potential commercialization of their gene therapy products, such as the ECUR-506. iECURE engages in B2B transactions, collaborating with hospitals and specialized clinics that treat patients with genetic disorders. Revenue is derived from milestone payments associated with clinical trial successes and eventual licensing agreements, integrating both upfront and milestone-based compensation structures, underscoring the company’s commitment to advancing gene therapy solutions while ensuring financial sustainability.In November 2022, iECURE, Inc. raised USD 65 mn in SERIES A funding co-led by new investors Novo Holdings and LYFE Capital, with participation from returning investors Versant Ventures and OrbiMed Advisors. The funding will be utilized to accelerate pre-IND activities, initiate clinical trials, and obtain clinical data from the Phase 1/2 clinical trial for gene editing products targeting rare liver diseases. iECURE aims to expand its product pipeline and increase its market presence, particularly in North America and Europe, focusing on developing innovative therapies that address unmet medical needs in genetic disorders.

## Funding rounds

- Series A, Nov 30, 2022, $65M — OrbiMed Advisors, Versant Ventures, Novo Holdings, LYFE Capital
- Series A, Sep 9, 2021, $50M — OrbiMed Advisors, Versant Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Novo Holdings — Series A
- LYFE Capital — Series A